Physician profile
Stephanie Doyle
NPI 1679747729
$5,782.91
in general payments reported to CMS, 2019-2025
25 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $1,502 · 2021: $1,256 · 2022: $474 · 2023: $589 · 2024: $697 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.68 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $998.26 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $970.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $537.79 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.77 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $256.54 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $247.95 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $184.74 | 2020-2021 | |
| Allergan, INC. | $179.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $119.00 | 2020-2024 | Trelegy Ellipta |
| Ani Pharmaceuticals, INC. | $114.95 | 2025 | Purified Cortrophin Gel |
| Amarin Pharma, INC. | $71.07 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.29 | 2019-2024 | Xifaxan |
| Pfizer INC. | $66.59 | 2019-2021 | |
| Astellas Pharma US INC | $61.24 | 2024-2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $54.19 | 2021 | |
| Nestle Healthcare Nutrition INC. | $53.86 | 2021 | |
| Sanofi Pasteur INC. | $31.77 | 2023 | |
| Sanofi-Aventis U.S. LLC | $28.34 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $25.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $23.96 | 2020 | |
| Sequel Med Tech, LLC | $19.20 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $14.03 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.56 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.